| Document |
Document Title |
|
WO/2024/076976A1 |
The disclosure provides polypeptides and polymers, and methods of using the same for reducing the risk of, preventing, or treating inflammation.
|
|
WO/2024/012569A9 |
The present disclosure relates to the biopharmaceutical field, in particular, to a linker for preparing targeting molecule-drug conjugates, and the corresponding conjugates, the preparing process and use thereof.
|
|
WO/2024/056874A1 |
The present invention relates to polypeptides comprising a first amino acid sequence comprising one or more GG repeat sequences and a peptide or polypeptide of interest in form of a fusion protein that exhibits increased renaturation eff...
|
|
WO/2024/059286A1 |
Disclosed in certain embodiments herein is a formulation including a plant-based growth factor and at least one of a peptide, an antioxidant and a botanical agent. The formulation has been found to improve the properties of the skin on t...
|
|
WO/2024/056875A1 |
The present invention relates to polypeptides comprising a first amino acid sequence comprising one or more GG repeat sequences and a peptide or polypeptide of interest in form of a fusion protein that exhibits increased renaturation eff...
|
|
WO/2024/047112A1 |
The present invention relates to halogenated somatostatin analogs with selectivity for multiple somatostatin receptor subtypes and pharmaceutical compositions comprising the same. Moreover, the present invention relates to said halogenat...
|
|
WO/2024/043250A1 |
The present invention addresses the problem of providing a cyclic peptide having a high cell membrane permeability or a salt thereof, and an MDMX inhibitor. The present invention provides a cyclic peptide that is represented by formula (...
|
|
WO/2024/043249A1 |
The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyc...
|
|
WO/2024/036890A1 |
The present invention relates to a TrkA antigen epitope peptide and a use thereof. The epitope peptide comprises an amino acid sequence as shown in SEQ ID NO: 4. The present invention obtains a dominant antigenic epitope of a TrkA antige...
|
|
WO/2024/034622A1 |
The purpose of the present invention is to provide a means for selecting a subject-derived neoantigen. The above problem is solved by providing, for example, a method for selecting a subject-derived neoantigen, said method comprising: ...
|
|
WO/2023/199134A1 |
The present invention provides an organometallic complex, which can be incorporated in a targeting smart delivery system to form a controlled-release multi-functional drug. In particular, the present invention relates to an organometalli...
|
|
WO/2023/190675A1 |
[Problem] To provide a novel compound having TrkB-binding activity. [Solution] A peptide complex having TrkB-binding activity comprises a first peptide having an amino acid sequence represented by X1-X2-X3-X4-3Py-W-X5-X6-X7-X8-X9-X10-V-X...
|
|
WO/2023/161197A1 |
The present invention relates to a method for the characterization of short peptides from proteins of industrial hemp seed flour (Cannabis Sativa L.). The present also relates to the mixture of short peptides obtained by this method.
|
|
WO/2023/096947A1 |
The crosslinked peptidomimetic macrocycles disclosed herein comprise an alkene or alkyne staple and a poly-amino acid C -terminal tail. These crosslinked peptidomimetic macrocycles have improved binding to MDM2 and MDMX (aka MDM4), are p...
|
|
WO/2022/221144A9 |
Embodiments of the claimed invention are directed to synthetic peptides comprising an amino acid sequence of X1X2VX3NLRGDLQVLX4QKVCX5T (SEQ ID NO:18), wherein at least one of X1 and X2 is a cysteine, and wherein one or more of X3, X4, an...
|
|
WO/2023/080136A1 |
Provided is a polypeptide having (a) an amino acid sequence described in SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 6, (b) an amino acid sequence having an identity of 80% or more with respect to an amino acid sequence described in SEQ ID...
|
|
WO/2023/028491A1 |
Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD). The composit...
|
|
WO/2023/028486A1 |
Disclosed herein are leukocyte-targeting molecules, pharmaceutical compositions comprising leukocyte-targeting molecules and an optional pharmaceutical agent, and methods of using same. In some embodiments, a leukocyte-targeting molecule...
|
|
WO/2023/010132A1 |
The methods and compositions of the disclosure are used to prevent or treat autoimmune diseases and disorders, such as lupus, by administering a PTPRS activating agent. The agent does not deplete pDCs or cause a general blockade of IFNα...
|
|
WO/2023/008556A1 |
The purpose of the present invention is to provide a drug which specifically binds to PSMA, which is effective in treatment and diagnosis of tumors or cancers that express PSMA, such as treatment and diagnosis of prostate cancer, especia...
|
|
WO/2022/272268A1 |
In one aspect, the present disclosure relates to an imaging agent comprising a detectable moiety covalently bound or coordinated to a "Moiety A" selected from a peptide, a chelator, or an organic compound comprising a leaving atom or a l...
|
|
WO/2022/226451A1 |
Disclosed herein are recombinant miropin polypeptides capable of inhibiting a broad spectrum of proteases, including Kgp and Rgp gingipains, trypsin, plasmin, elastase, cathepsin G, cathepsin L, and plasma kallikrein. Also disclosed here...
|
|
WO/2022/224980A1 |
The present invention addresses the problem of providing a complex that has higher stability than in the past without reducing drug efficacy. The complex of the present invention is a complex of an anti-CD20 antibody and a chelating agen...
|
|
WO/2022/226297A1 |
Antimicrobial peptides and methods of use are provided.
|
|
WO/2022/218331A1 |
Provided herein are a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.
|
|
WO/2022/215495A1 |
The present invention addresses the problem of providing a means for reducing the bioburden of a cyclic lipopeptide compound product through a simple operation without loss of quality or function thereof. The present invention pertains...
|
|
WO/2022/205822A1 |
The present invention belongs to the technical field of biomedicine, and provided therein are a cathelicidin for inhibiting novel coronavirus infections, a composition thereof, and a related use thereof. In the composition, a cathelicidi...
|
|
WO/2022/202785A1 |
A purpose of the present invention is to provide a method for efficient cell fusion. Also, a purpose of the present invention is to provide a method for killing cancer cells or a method for fusing a viral envelope by membrane fusion. T...
|
|
WO/2022/203000A1 |
The present invention addresses the problem of providing a fusion protein that is for use in treatment or diagnosis of cancer and that is formed between a streptavidin variant and a molecule that recognizes a cancer cell or the like. The...
|
|
WO/2022/189639A1 |
The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of t...
|
|
WO/2022/184821A1 |
The present invention relates to the field of microbiology, in particular to the field of bacterial antibiotic resistance, more particularly to the field of resistance to beta-lactam inhibitors. The invention provides non-natural compoun...
|
|
WO/2022/160156A1 |
The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase ...
|
|
WO/2022/158977A1 |
The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (...
|
|
WO/2022/136628A1 |
The present invention refers to the medical field. Particularly, it refers to a method for determining whether an immune response has occurred in subjects who have been infected with- or vaccinated against coronavirus.
|
|
WO/2022/109058A1 |
The present disclosure provides systems, methods, and compositions for the delivery of one or more components of a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas (CRISPR associated protein) gene editing system.
|
|
WO/2022/092295A1 |
The present disclosure provides a novel crosslinked peptide. The present disclosure provides a crosslinked peptide that contains a crosslinked portion and a peptide portion, wherein, when the carbon atom at which the crosslinked portion ...
|
|
WO/2022/046941A1 |
Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, a linker and a drug. The drug is an antimitotic tetrapeptide. Methods of use of the ADCs are also
|
|
WO/2022/037681A1 |
A bioinformatic method is used to analyze, discover and predict, from human intestinal metagenomics, peptides having microorganism inhibiting activity, that is, antimicrobial peptides, and the activity thereof is confirmed by means of ex...
|
|
WO/2022/026867A1 |
The present invention provides for methods of treating solid tumors, particularly, KRas mutated solid tumors and KRas mutated pancreatic cancer. The method includes administering glutamine alone or in combination with an anti-cancer agen...
|
|
WO/2022/005899A1 |
The present disclosure provides human 1L-23R (WL-23R) binding polypeptides, conditionally maximally active SilL~23R binding proteins, multimers thereof, and methods for using the polypeptides and binding proteins for therapeutic use.
|
|
WO/2021/246392A1 |
A lactic acid bacteria growth promoter which has a growth promotion effect on lactic acid bacteria is provided. This lactic acid bacteria growth promoter contains at least one type of peptide selected from a first peptide, in which the t...
|
|
WO/2021/138397A1 |
The present disclosure provides modified looped proteins comprising at least one looped region, wherein the at least one looped region comprises a cell penetrating peptide (CPP). In some embodiments, the present disclosure provides polyn...
|
|
WO/2021/136475A1 |
A linker molecule for targeting molecule-drug conjugate, has the structure of formula (I): A1p-D1q-Y-Lk-W-A2q-D2p (I). A conjugate has the structure of formula (III): A-((compound of formula (I))-PL t) z (III). The conjugate can be used ...
|
|
WO/2021/127294A1 |
A contraceptive device is provided which includes a (preferably elastomeric) surface; and a lubricant applied to the surface. The lubricant includes (a) a lubricious medium, and (b) a pharmaceutically effective amount of a peptoid dispos...
|
|
WO/2021/069426A2 |
The treatment according to the invention provides the use of at least one peptide having the general Formula X-(Xaa)nK*TTK*X'aa-(Xaa)m-Z for a non-therapeutic cosmetic treatment of keratinous tissues of the skin and of its appendages. In...
|
|
WO/2021/072392A1 |
Disclosed are agents and methods of using the agents to treat or prevent pain and/or induce anesthesia. The agents may be peptides, siRNAs, and/or shRNAs that target adaptin protein 2-clathrin mediated endocytosis (AP2-CME). Peptides of ...
|
|
WO/2021/054448A1 |
Purposes of the present invention include: providing an efficient cell fusion method; and providing a method for killing cancer cells through cell fusion. The purposes are achieved by: (1) a polypeptide having an amino acid sequence se...
|
|
WO/2021/005019A1 |
The invention relates to isolated synthetic or recombinant peptides comprising an epitope of human tau 2N4R, wherein the tau peptide sequence comprising the epitope is not phosphorylated. The invention also relates to use of such peptide...
|
|
WO/2020/232407A9 |
The invention features peptide antibiotic compositions and methods of using such compositions for the treatment of bacterial infections (e.g., vancomycin resistant infections).
|
|
WO/2020/232440A1 |
Alzheimer's disease (AD) pathology is characterized by plaques of amyloid beta (Aβ) and neurofibrillary tangles of tau. Aβ aggregation is thought to occur at early stages of the disease, and ultimately gives way to the formation of tau...
|
